TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03531450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Treatment sessions will use active, structured techniques to alter distorted thoughts, with a focus on acquiring and practicing cognitive and emotional modulatory skills. In particular, cognitive restructuring is used to help patients recognize the relationships between thoughts, feelings, and behaviors. Patients learn to identify, evaluate, and challenge negative thoughts. Patients will also learn behavioral strategies to decrease avoidance behavior and increase toleration of physical sensations.
Study: NCT03742063

Intervention type: DRUG
Intervention: first-line chemotherapy
Description: patients who routinely received neoadjuvant chemotherapy according to Peking University People's Hospital chemo-protocols (PKUPH-OS and PKUPH-ES)

Intervention type: DRUG
Intervention: first-line chemotherapy
Description: patients who routinely received neoadjuvant chemotherapy according to Peking University People's Hospital chemo-protocols (PKUPH-OS and PKUPH-ES)

Intervention type: DRUG
Intervention: first-line chemotherapy
Description: patients who routinely received neoadjuvant chemotherapy according to Peking University People's Hospital chemo-protocols (PKUPH-OS and PKUPH-ES)
Study: NCT03050840

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Way to Health
Description: An online platform (Way to Health) will be used to test if self-monitoring plus gamification principles can increase steps per day and lower sugar sweetened beverage consumption per day, among obese children and adults, compared to self-monitoring alone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Way to Health
Description: An online platform (Way to Health) will be used to test if self-monitoring plus gamification principles can increase steps per day and lower sugar sweetened beverage consumption per day, among obese children and adults, compared to self-monitoring alone.
Study: NCT02977143

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid loading of volulyte 300 ml
Description: Administration of volulyte 300 ml and measurement of increase in cardiac index
Study: NCT03742063

Intervention type: DRUG
Intervention: first-line chemotherapy
Description: patients who routinely received neoadjuvant chemotherapy according to Peking University People's Hospital chemo-protocols (PKUPH-OS and PKUPH-ES)
Study: NCT02790658

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Intake of grumixama juice
Description: In the morning of experimental day after 10 h fasting, the volunteers have been collect the first urine in the morning and it was collected the blood before the intake of grumixama juice, after they drink the juice (0 min), it was collected blood at the times: 15 min, 30 min, 60 min,120 min, 240 min and 24 h; and it was also collected urine at the period: 0 -1h, 1 - 2h, 2 - 4h, 4 - 6 h, 6 - 12 h, 12 - 14 h, the first urine in the morning in the second day (24 h). During the period in the first 4 h of experiment the volunteers only intake the juice.
Study: NCT03548480

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention with a daily dose of placebo
Study: NCT03563638

Intervention type: DIAGNOSTIC_TEST
Intervention: 75gOGTT
Description: oral glucose tolerance test (OGTT) was conducted on all participants between the 24th and 28th gestation weeks.The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded: FPG≥5.1 mmol/L and/or 1h-PG ≥10.0 mmol/L and/or 2h-PG ≥8.5 mmol/ L.

Intervention type: DIAGNOSTIC_TEST
Intervention: 75gOGTT
Description: oral glucose tolerance test (OGTT) was conducted on all participants between the 24th and 28th gestation weeks.The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded: FPG≥5.1 mmol/L and/or 1h-PG ≥10.0 mmol/L and/or 2h-PG ≥8.5 mmol/ L.
Study: NCT03548480

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Intervention with a daily dose of probiotic
Study: NCT02368262

Intervention type: OTHER
Intervention: Questionnaire and micturition and drinking diaries
Description: Questionnaire: ICCS parental questionnaire + extended history taking document, ROME III criteria, demographic information and/or PIN-Q.~Diaries: 24-hour voiding chart

Intervention type: OTHER
Intervention: Questionnaire and micturition and drinking diaries
Description: Questionnaire: ICCS parental questionnaire + extended history taking document, ROME III criteria, demographic information and/or PIN-Q.~Diaries: 24-hour voiding chart

Intervention type: OTHER
Intervention: Questionnaire and micturition and drinking diaries
Description: Questionnaire: ICCS parental questionnaire + extended history taking document, ROME III criteria, demographic information and/or PIN-Q.~Diaries: 24-hour voiding chart

Intervention type: OTHER
Intervention: Questionnaire and micturition and drinking diaries
Description: Questionnaire: ICCS parental questionnaire + extended history taking document, ROME III criteria, demographic information and/or PIN-Q.~Diaries: 24-hour voiding chart

Intervention type: PROCEDURE
Intervention: Uroflowmetry, pelvic floor EMG and bladderscan
Description: Voiding variables, pelvic floor activity during micturition and postmictional residue.

Intervention type: PROCEDURE
Intervention: Uroflowmetry, pelvic floor EMG and bladderscan
Description: Voiding variables, pelvic floor activity during micturition and postmictional residue.

Intervention type: PROCEDURE
Intervention: Uroflowmetry, pelvic floor EMG and bladderscan
Description: Voiding variables, pelvic floor activity during micturition and postmictional residue.

Intervention type: PROCEDURE
Intervention: Uroflowmetry, pelvic floor EMG and bladderscan
Description: Voiding variables, pelvic floor activity during micturition and postmictional residue.
Study: NCT02383706

Intervention type: DEVICE
Intervention: ApneaLink Air
Description: Overnight, home polysomnography device

Intervention type: BEHAVIORAL
Intervention: Berlin Quesionnaire
Description: OSA screening questionnaire

Intervention type: BEHAVIORAL
Intervention: Epworth Sleepiness Scale
Description: OSA screening questionnaire

Intervention type: BEHAVIORAL
Intervention: STOP-BANG questionnaire
Description: OSA screening questionnaire

Intervention type: OTHER
Intervention: Physical exam
Description: Physical exam of neck, mouth and upper airway
Study: NCT00924963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-Tip jet injector
Description: 0.2ml 1%buffered lidocaine delivered by jet injector

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Jet injection saline
Description: 0.2ml saline delivered via J-Tip jet injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine cream
Description: 4% lidocaine cream applied for 30 minutes to the skin
Study: NCT04476563

Intervention type: DIAGNOSTIC_TEST
Intervention: Obtaining biological samples
Description: Biological samples (blood, urine, stool). Liver tissue will be obtained from ChILI group when clinically indicated

Intervention type: DIAGNOSTIC_TEST
Intervention: Obtaining biological samples
Description: Biological samples (blood, urine, stool). Liver tissue will be obtained from ChILI group when clinically indicated
Study: NCT04667390

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: total knee arthroplasty

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: total knee arthroplasty

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: total knee arthroplasty
Study: NCT01715779

Intervention type: DRUG
Intervention: Eltrombopag
Description: Eltrombopag exposure
Study: NCT01742403

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: R/T gating kV intrafraction monitoring
Description: This is a Phase I Pilot study to assess the feasibility of implementing prostate radiotherapy gating using kV intrafraction monitoring.
Study: NCT02413008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estriol
Description: 0.005% estriol vaginal gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo vaginal gel
Study: NCT02941939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric chamber

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambient pressure
Study: NCT00904280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER
Description: Open label
Study: NCT01494090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 5 or 20 mg per day during 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 or 20 mg per day during 6 months
Study: NCT02702635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCE MRI of the brain
Description: An MRI of the brain including a DCE sequence
Study: NCT03136562

Intervention type: DIAGNOSTIC_TEST
Intervention: Synacthen test
Description: 250 microg synacthen test performed fasting, in the morning. P-cortisol measured before and 30 minutes after Synacthen injection.
Study: NCT02654106

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiotherapy
Description: The regular fraction modes were as follows: a. lesions≥3 cm：52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions\<2cm：36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm：40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem：50-60Gy/2.5-3Gy/20f.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/m2\*5d, q28d, 6cycles
Study: NCT00308061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP1/AS02A
Description: FMP1 antigen contained 62.5 ug of lyophilized protein with 3.1 percent lactose as cryoprotectant. It's reconstituted in approx. 600 uL AS02A adjuvant manufactured by GSK. AS02A contains 50 ug MPL and 50ug QS21, 250uL of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 mL. All AS02A vials contained 0.65 to 0.75 mL of liquid.
Study: NCT03418363

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Daily oral capsule
Study: NCT01783808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Description: Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used.
Study: NCT00308061

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Imovax Rabies Vaccine
Description: Sterile, stable, freeze-dried suspension of rabies virus prepared from the strain PM-1503-3M, obtained from the Wistar Inst. in Philadelphia. Each 1 mL dose of vaccine contained 100 mg of human albumin, \<150g of neomycin sulfate, and \>2.5 IU of rabies antigen.
Study: NCT03548922

Intervention type: OTHER
Intervention: Tanner stage
Description: a scale of pubertal development in children, adolescents

Intervention type: OTHER
Intervention: Risser stage
Description: a measure showing the growth left in the spine

Intervention type: OTHER
Intervention: Pressure of correction
Description: an indirect parameter of the chest wall's flexibility. It is defined as the pressure applied to the patient, in the most protruding area of the chest, needed to accomplish a proper shape of the thorax.

Intervention type: OTHER
Intervention: Pectus carinatum protrusion
Description: distance from the point of maximum protrusion to the estimated normal level of chest wall
Study: NCT01582555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline nasal irrigation alone
Description: control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation
Study: NCT01092624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex
Description: There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
Study: NCT01582555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dissolved N-Acetylcystine
Description: intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
Study: NCT01627093

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical records

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT01092624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex
Description: There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
Study: NCT00741273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: Proellex 25 mg capsule, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: Proellex 25 mg capsule, single dose
Study: NCT02036060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d
Description: Docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d in 21 day cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel 75 mg/m2 + prednisone 10 mg/d
Description: Docetaxel 75 mg/m2 plus prednisone 10 mg/d in 21 day cycles.
Study: NCT03005288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYM338 10 mg/kg
Description: intravenous infusion every four weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion every four weeks
Study: NCT02393261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2500ml Huaren peritoneal dialysate
Description: use 2-3 bags of 2500ml Huaren dialysate in the daytime and keep 1 bag of 2500ml Huaren dialysate in the night

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2000ml peritoneal dialysate
Description: use 3-4 bags of normal 2000ml dialysate in the daytime and keep 1 bag of 2000ml dialysate in the night
Study: NCT03020355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placental Blood Drainage
Description: Immediately after vaginal delivery, after clamping and cutting the cord-the cord will unclamped and the blood will drained until the flow ceased.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: not Placental Blood Drainage
Description: In the control group, the clamped cord will not released.
Study: NCT01983345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prenatal surgical repair of fetal myelomeningocele
Description: open surgical repair of myelomeningocele before 26 weeks gestational age
Study: NCT04319289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic interval training and Vitamin D supplementation,
Description: The participants in both groups A will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age .~* Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting HR~* Frequency: 3 days/week., for 12 weeks~Also all participants in this group are taking gne capsule containing (cholecalciferol 400 IU) every day .
Study: NCT04993118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Neuromuscular Inhibition technique
Description: Integrated Neuromuscular inhibition technique At first ischemic compression was given using a pincer grip over the active trigger point till the tissue barrier was felt .The process was repeated till the tension reduced for 90 seconds.Ischemic compression was followed by the application of strain counterstrain. Once the position of ease was identiﬁed, it was held for 90 seconds and repeated for three to ﬁve repetitions. Muscle energy technique was applied as last part of integrated neuromuscular inhibition technique . Each isometric contraction was held for 7-10 seconds and was followed by further contralateral side bending, ﬂexion, and ipsilateral rotation to maintain the soft tissue stretch. Each stretch was held for 30 seconds and was repeated three to ﬁve times per treatment session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic Compression,Hotpack,TENS
Description: Control group received conventional physical therapy. It included HOT Packs ( 20 minutes) , TENS (10 minutes) ,Ischemic compression .Using a pincer grasp, we identified the trigger point. Once the trigger point was identiﬁed we applied ischemic compression by placing the thumb and index ﬁnger over the active TrP. Slow, increasing levels of pressure was applied until the tissue resistance barrier was identiﬁed. Pressure was maintained until a release of the tissue barrier was felt. At that time, pressure was again applied until a new barrier was felt. This process was repeated until tension/tenderness is unable to be identiﬁed
Study: NCT02237079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene/Conjugated Estrogens (BZA/CE)
Description: Daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Daily placebo tablet
Study: NCT01077661

Intervention type: DRUG
Intervention: Nebivolol
Description: patients administrated Nebivolol according to the prescribing information
Study: NCT00771628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flex-It Stylet
Description: Patients will be intubated using the GlideScope with an ETT fitted with a Flex-It stylet.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard malleable stylet
Description: Patients will be intubated using the GlideScope with an ETT fitted with a standard malleable stylet.
Study: NCT04319289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation only
Description: One capsule containing (cholecalciferol 400 IU) was taken every day .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic interval training only
Description: The participants in group C will be instructed to perform aerobic interval exercises at 70% maxHR for 5 minutes and then decrease activity to 50% for 5 minutes and repeat for the length of the activity (the training will be done by using bicycle ergometer(Biodex LBC, Biodex Inc., New York).• Before starting training ; Maximum heart rate calculated from the following equation: maxHR= 220-age (Gellish ,2007).~* Duration: the first five to ten minutes of each session were dedicated to warming up exercise on the bicycle in the form of slow progression exercise (to decrease the risk of hypotension, musculoskeletal injury and cardiovascular complications), followed by the active phase of exercise for 40 min., and finally cooling down phase for ten minutes. with intensity and speed decreased gradually until reaching the resting heart rate (Broderick et al.,2014).~* Frequency: 3 days/week. The whole training lasting for 12 weeks
Study: NCT02583698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo